Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentre, multinational, randomised, double blind, placebo-controlled study on Sulodexide for the management of leg symptoms in patients with chronic venous disease VEINS (VEnous INvestigation with Sulodexide)

Next Previous
X
Search
Trial Profile

Multicentre, multinational, randomised, double blind, placebo-controlled study on Sulodexide for the management of leg symptoms in patients with chronic venous disease VEINS (VEnous INvestigation with Sulodexide)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Feb 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sulodexide (Primary)
  • Indications Venous insufficiency
  • Focus Therapeutic Use
  • Acronyms VEINS
  • Sponsors Alfasigma

    • Most Recent Events

    • 02 Feb 2023 This trial has been completed in Poland according to European Clinical Trials Database record.
    • 22 Dec 2022 Planned End Date changed from 5 Jan 2023 to 8 Jul 2023.
    • 22 Dec 2022 The study has been completed in Czechia as per Eudra record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top